Changes in Beneficial Ownership · 4
Arcutis Biotherapeutics, Inc.
ARQTNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1787953199.xml
Filing details
- Report period
- 2026-08-27
- Issuer
- Arcutis Biotherapeutics, Inc.
- Issuer CIK
- 0001787306
- Trading symbol
- ARQT
Reporting owner 1
- Name
- Curran Terrie
- Reporting owner CIK
- 0001690298
- Relationship
- Director
- Address
- C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE, CA, 91361
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-27 | M · Form 4[F1] | 11,148 | A | 7.51 | 34,674 | D |
| Common Stock | 2026-08-27 | S · Form 4[F1] | 11,148 | D | 25.0294[F2] | 23,526 | D |
| Common Stock | 2026-08-27 | M · Form 4[F3] | 27,052 | A | 8.63 | 50,578 | D |
| Common Stock | 2026-08-27 | S · Form 4[F3] | 27,052 | D | 25.0294[F2] | 23,526 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | 7.51 | 2026-08-27 | M · Form 4[F1] | 11,148 | D | 0 | [F4] | 2033-05-31 | Common Stock | 11,148 | 0 | D |
| Stock Option (right to buy) | 8.63 | 2026-08-27 | M · Form 4[F3] | 27,052 | D | 0 | [F4] | 2034-06-14 | Common Stock | 27,052 | 0 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.↩ 1↩ 2↩ 3
- F2
- The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.↩ 1↩ 2
Signature 1
- Signed
- /s/ Latha Vairavan, as Attorney-in-Fact for Terrie Curran
- Date
- 2026-08-28